Understanding predictors of recurrent hyperkalemia may help health care providers provide a more individualized approach to hyperkalemia management. Hyperkalemia recurrence is more likely in patients ...

A recent population-based study assessed the incidence of clinically significant hyperkalemia among adult CKD patients being treated with RAASis and how this affected future treatment. In the study, 9 ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

New findings have important implications in the new era where delaying dialysis initiation is a priority goal by means of continued conservative management of hyperkalemia, according to investigators.

Those with chronic kidney disease, heart failure, diabetes, and hypertension bear an increased burden of hyperkalemia. Untreated hyperkalemia can lead to life-threatening neuromuscular and cardiac ...

Synthetic ion-exchange resins were first made available to industry in 1935 and have since been extensively adapted to . . . From the Cardio-Renal Laboratory, Second (Cornell) Medical Division, ...

Please provide your email address to receive an email when new articles are posted on . During study follow-up, 93 patients developed kidney failure with replacement therapy and 134 patients died.

WASHINGTON, DC—The oral potassium-binding agent patiromer (Veltassa; Vifor Pharma) may help keep hyperkalemia under control in heart failure with reduced ejection fraction (HFrEF) patients taking ...

ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd.

Please provide your email address to receive an email when new articles are posted on . An analysis of transgender teens prescribed spironolactone showed that only 2.2% developed hyperkalemia after ...